Cai Hongfu, Lin Jingwen, Zhu Huide, Zheng Zhiwei
Department of Pharmacy, Fujian Medical University Union Hospital, Fuzhou, China.
Department of Pharmacy, Cancer Hospital of Shantou University Medical College, Shantou, China.
BMJ Open. 2024 Dec 11;14(12):e079603. doi: 10.1136/bmjopen-2023-079603.
The objective of this research is to assess the cost-effectiveness of combining camrelizumab with rivoceranib in comparison to sorafenib as first-line therapeutic options for advanced hepatocellular carcinoma from the Chinese medical system perspective.
A partitioned survival model was employed to perform a comprehensive cost-effectiveness analysis. This analysis incorporated multiple factors, such as treatment effectiveness, adverse events and costs, all of which were derived from data obtained from the CARES-310 trial. Furthermore, sensitivity analyses were conducted to evaluate the robustness and reliability of the model.
The comparison between the two groups demonstrated that the cohort receiving camrelizumab combined with rivoceranib exhibited a significant increase of 0.803 quality-adjusted life year (QALY), alongside an additional expenditure of US$7345.051. This computation resulted in an incremental cost-effectiveness ratio of US$9147.012 per QALY, which was lower than the willingness-to-pay threshold of US$39 855.785 per QALY in China. Sensitivity analyses conducted in this study further demonstrated the robustness of the results across various assumptions.
The adoption of camrelizumab plus rivoceranib as a treatment option is not only associated with improved health outcomes but also represents a cost-effective choice in China.
本研究旨在从中国医疗体系角度评估卡瑞利珠单抗联合瑞沃替尼与索拉非尼作为晚期肝细胞癌一线治疗方案的成本效益。
采用分区生存模型进行全面的成本效益分析。该分析纳入了多个因素，如治疗效果、不良事件和成本，所有这些均来自CARES - 310试验获得的数据。此外，还进行了敏感性分析以评估模型的稳健性和可靠性。
两组之间的比较表明，接受卡瑞利珠单抗联合瑞沃替尼的队列的质量调整生命年（QALY）显著增加了0.803，同时额外支出7345.051美元。由此计算得出的每QALY增量成本效益比为9147.012美元，低于中国每QALY 39855.785美元的支付意愿阈值。本研究进行的敏感性分析进一步证明了结果在各种假设下的稳健性。
在中国，采用卡瑞利珠单抗联合瑞沃替尼作为治疗方案不仅与改善健康结果相关，而且是一种具有成本效益的选择。
